title: Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.
abstract: Immunogenic cell death (ICD) is a form of cell death that activates an adaptive immune response against dead-cell-associated antigens. Cancer cells killed via ICD can elicit antitumor immunity. ICD is efficiently induced by near-infrared photo-immunotherapy (NIR-PIT) that selectively kills target-cells on which antibody-photoabsorber conjugates bind and are activated by NIR light exposure. Advanced live cell microscopies showed that NIR-PIT caused rapid and irreversible damage to the cell membrane function leading to swelling and bursting, releasing intracellular components due to the influx of water into the cell. The process also induces relocation of ICD bio markers including calreticulin, Hsp70 and Hsp90 to the cell surface and the rapid release of immunogenic signals including ATP and HMGB1 followed by maturation of immature dendritic cells. Thus, NIR-PIT is a therapy that kills tumor cells by ICD, eliciting a host immune response against tumor.
authors.affiliation: Medical Photonics Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.|Laboratory for Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.
authors.forename: Mikako
authors.initials: M
authors.lastname: Ogawa
authors.affiliation: Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tomita
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Min-Jung
authors.initials: MJ
authors.lastname: Lee
authors.affiliation: Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Sunmin
authors.initials: S
authors.lastname: Lee
authors.affiliation: Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Saori
authors.initials: S
authors.lastname: Tomita
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Tadanobu
authors.initials: T
authors.lastname: Nagaya
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Sato
authors.affiliation: Central Research Laboratory, Hamamatsu Photonics K. K., Hamamatsu 434-8601, Japan.
authors.forename: Toyohiko
authors.initials: T
authors.lastname: Yamauchi
authors.affiliation: Central Research Laboratory, Hamamatsu Photonics K. K., Hamamatsu 434-8601, Japan.
authors.forename: Hidenao
authors.initials: H
authors.lastname: Iwai
authors.affiliation: Section on High Resolution Optical Imaging, NIBIB/NIH, Bethesda, MD 20892, USA.
authors.forename: Abhishek
authors.initials: A
authors.lastname: Kumar
authors.affiliation: Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Haystead
authors.affiliation: Section on High Resolution Optical Imaging, NIBIB/NIH, Bethesda, MD 20892, USA.
authors.forename: Hari
authors.initials: H
authors.lastname: Shroff
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Choyke
authors.affiliation: Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Jane B
authors.initials: JB
authors.lastname: Trepel
authors.affiliation: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Hisataka
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology*; D037282:Calreticulin / Q000378:metabolism; D045744:Cell Line, Tumor; D000068818:Cetuximab / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D005260:Female; D024243:HMGB1 Protein / Q000378:metabolism; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007259:Infrared Rays; D051379:Mice; D008819:Mice, Nude; D008853:Microscopy / Q000379:methods; D041681:NIH 3T3 Cells; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D017319:Photosensitizing Agents / Q000494:pharmacology*; D010789:Phototherapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D013997:Time Factors; D014162:Transfection; D000068878:Trastuzumab / Q000494:pharmacology*; D019139:Tumor Escape; D023041:Xenograft Model Antitumor Assays
chemical_list: D000255:Adenosine Triphosphate; D000074322:Antineoplastic Agents, Immunological; D037282:Calreticulin; D000068818:Cetuximab; D066246:ErbB Receptors; D024243:HMGB1 Protein; D018840:HSP70 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins; D017319:Photosensitizing Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C576483:CALR protein, human; C585491:HMGB1 protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human
keywords: immunogenic cell death; near infrared photoimmunotherapy